Our attorneys have filed a mass tort lawsuit on behalf of sufferers who took the blood thinner Xarelto (rivaroxaban) and suffered severe bleeding events. Pharmaceutical companies, like the makers of Xarelto, have a duty to make sure that their drugs are reasonably safe for use – and failure to accomplish so may possibly be grounds for compensation. Our lawyers are working challenging to have these hurt by the drug the compensation they may be entitled to.
Whilst bleeding can be a frequent complication associated with anticoagulants, it has been alleged that Xarelto is much more dangerous than traditional blood thinners simply because no antidote exists to reverse its blood-thinning effects. This indicates that, inside the event of an emergency, patients may possibly be at threat for irreversible bleeding difficulties, which includes life-threatening internal and gastrointestinal hemorrhaging.
Should you or perhaps a loved one particular suffered a critical bleeding event soon after taking Xarelto, you may have legal recourse. For much more information, get in touch with us right now to have your case reviewed, totally free of charge.
Compensation Possibilities
xarelto-compensation-photoThe plaintiffs in these lawsuits are searching for compensation from Bayer and Janssen for past and future medical bills, lost wages, discomfort and suffering and, in situations of death, funeral expenses. Furthermore, they may be seeking punitive damages, which are usually awarded to punish the defendant and deter other companies from acting similarly.
Why Are Lawsuits Getting Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several xarelto prescribing information lawsuits alleging that the drug is dangerous and defective. The plaintiffs claim that, unlike traditional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Since of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding in the event of an emergency. Plaintiffs inside the lawsuits allege significant and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and healthcare staff were not properly made aware of methods to stabilize and treat a Xarelto user within the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding occasion.
Xarelto is linked to critical bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing dangerous clotting.
Visit this page for far more data on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.